Search…

Lates News

27/03/2026

AstraZeneca's stock price rose by 3.3% after the company announced that its experimental drug, Tozolizumab, met its primary endpoints in two late-stage clinical trials.

Latest

5 m ago

Tieke Railway: Net profit in 2025 is 171 million yuan, a year-on-year decrease of 20.09%.

5 m ago

Every Economist AI newsletter, Donghai Securities published a research report on March 27 giving Boya Bio (300294.SZ) a "buy" rating. The reasons for the rating mainly include: 1) The decline in profit margins is significant due to the impact of large provision; 2) The revenue growth of the blood products business is increasing, but the gross profit margin is under short-term pressure; 3) Plasma collection volume is steadily increasing, and product pipeline is continuously expanding. (Daily Economic News)

5 m ago

Dividend insurance demonstration interest rate is planned to be lowered to 3.5%.

5 m ago

Cenway Research: After changing the investment project, open a special account and sign a four-party supervision agreement.

5 m ago

Rolande Company: It intends to seek and obtain exploration, development, and mining rights of mineral assets in Venezuela in accordance with the country's new mining system.

+852 - 60190728

Customer Support

Commercial Services